• Japanese
  • Korean
  • Chinese
Cover Image

Hematology Partnering Terms and Agreements

The Hematology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the hematology partnering deals and agreements entered into by the worlds leading healthcare companies

Description

The Hematology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the hematology partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in hematology partnering deals

Average deal terms for headline, upfront and royalty by stage of development

Hematology partnering agreement structure

Hematology partnering contract documents

Top hematology deals by value

Most active hematology dealmakers

The Hematology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the hematology partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter hematology partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors infectives technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1,000 links to online copies of actual hematology deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of hematology dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in hematology dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading hematology deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top bigpharma companies with a brief summary followed by a comprehensive listing of hematology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all hematology deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all hematology partnering deals signed and announced since 2009. The chapter is organized by specific hematology therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all hematology partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in hematology partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of hematology technologies and products.

Report scope

Hematology Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to hematology trends and structure of deals entered into by leading companies worldwide.

Hematology Partnering Terms and Agreements includes:

  • Trends in hematology dealmaking in the biopharma industry since 2009
  • Analysis of hematology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of hematology deal contract documents
  • Comprehensive access to over 1,000 hematology deal records
  • The leading hematology deals by value since 2009
  • Most active hematology dealmakers since 2009

In Hematology Partnering Terms and Agreements, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Hematology Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,000 hematology deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise hematology rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Hematology Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of hematology deal trends since 2009
  • Access infectives deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between hematology partner companies
  • Comprehensive access to over 1,000 links to actual hematology deals entered into by the world's biopharma companies
  • Indepth review of hematology deals entered into by the leading fifty bigpharma companies
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner hematology opportunities
  • Uncover companies actively partnering hematology opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in hematology dealmaking

  • 2.1. Introduction
  • 2.2. Hematology partnering over the years
  • 2.3. Bigpharma hematology dealmaking activity
  • 2.4. Bigpharma not active in hematology
  • 2.5. Hematology partnering by deal type
  • 2.6. Hematology partnering by industry sector
  • 2.7. Hematology partnering by stage of development
  • 2.8. Hematology partnering by technology type
  • 2.9. Hematology partnering by hematology indication
  • 2.10. Average deal terms for hematology
  • 2.10.1 Hematology headline values
  • 2.10.2 Hematology upfront payments
  • 2.10.3 Hematology milestone payments
  • 2.10.4 Hematology royalty rates

Chapter 3 - Leading hematology deals

  • 3.1. Introduction
  • 3.2. Top hematology deals by value
  • 3.3. Top hematology deals involving bigpharma

Chapter 4 - Bigpharma hematology deals

  • 4.1. Introduction
  • 4.2. How to use bigpharma partnering deals
  • 4.3. Bigpharma hematology partnering company profiles
  • Amgen
  • Astellas
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Biogen Idec
  • Bristol-Myers Squibb
  • Celgene
  • CSL
  • Daiichi Sankyo
  • Eisai
  • Eli Lilly
  • GlaxoSmithKline
  • Grifols
  • Hospira
  • Johnson & Johnson
  • Janssen Biotech
  • Lundbeck
  • Menarini
  • Merck & Co
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Purdue
  • Roche
  • Sanofi
  • Shire
  • Takeda
  • Teva
  • Watson

Chapter 5 - Hematology partnering contracts directory

  • 5.1. Introduction
  • 5.2. By deal type
  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Contract service
  • Co-promotion
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Research
  • Settlement
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • 5.3. By stage of development
  • Discovery
  • Formulation
  • Marketed
  • Phase I
  • Phase II
  • Phase III
  • Preclinical
  • Regulatory
  • 5.4. By technology type
  • Analysis
  • Assays
  • Biological compounds
  • Biomaterials
  • Blood products
  • Cell therapy
  • Clinical testing
  • Devices
  • Diagnostics
  • Discovery tools
  • Drug delivery
  • Enabling technology
  • Equipment
  • Facilities
  • Genomics
  • Industrial chemicals
  • Nanotechnology
  • Oligonucleotide
  • Orphan drug
  • Packaging
  • Peptides
  • Processes
  • Proteomics
  • Radio/Chemo-therapy
  • Recombinant DNA
  • Regenerative medicine
  • Research services
  • Research supplies
  • RNA therapeutics
  • Screening
  • Small molecules
  • Software tools
  • Stem cells

Chapter 6 - Hematology dealmaking by indication

  • 6.1. Introduction
  • 6.2. Deals by therapeutic indication
  • Hematology
  • Anemia
  • Iron deficiency
  • Blood substitute
  • Neutropenia
  • Polycythemia
  • Thalassemia
  • Thrombocytopenia
  • Vitamin K Deficiency
  • Von-Willebrand disease

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Directory of hematology deals by company A-Z 2009-2014
  • Appendix 2 - Directory of hematology deals by deal type 2009-2014
  • Appendix 3 - Directory of hematology deals by stage of development 2009-2014
  • Appendix 4 - Directory of hematology deals by technology type 2009-2014
  • Appendix 5 - Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent titles from CurrentPartnering
  • Order Form - Reports
  • Table of figures
  • Figure 1: Hematology partnering since 2009
  • Figure 2: Bigpharma - top 50 - hematology deals 2009 to 2012
  • Figure 3: Bigpharma hematology deal frequency - 2009 to 2012
  • Figure 4: Inactive bigpharma in hematology 2009-2014
  • Figure 5: Hematology partnering by deal type since 2009
  • Figure 6: Hematology partnering by industry sector since 2009
  • Figure 7: Hematology partnering by stage of development since 2009
  • Figure 8: Hematology partnering by technology type since 2009
  • Figure 9: Hematology partnering by hematology target since 2009
  • Figure 10: Hematology deals with a headline value
  • Figure 11: Hematology deal headline value distribution, US$million - discovery stage
  • Figure 12: Hematology deal headline value distribution, US$million - preclinical stage
  • Figure 13: Hematology deal headline value distribution, US$million - phase I stage
  • Figure 14: Hematology deal headline value distribution, US$million - phase II stage
  • Figure 15: Hematology deal headline value distribution, US$million - phase III stage
  • Figure 16: Hematology deal headline value distribution, US$million - regulatory stage
  • Figure 17: Hematology deal headline value distribution, US$million - marketed stage
  • Figure 18: Summary median headline value by stage of development, 2009-2014
  • Figure 19: Hematology deals with upfront payment values
  • Figure 20: Hematology deal upfront payment distribution, US$million - discovery stage
  • Figure 21: Hematology deal upfront payment distribution, US$million - preclinical stage
  • Figure 22: Hematology deal upfront payment distribution, US$million - phase I stage
  • Figure 23: Hematology deal upfront payment distribution, US$million - phase II stage
  • Figure 24: Hematology deal upfront payment distribution, US$million - phase III stage
  • Figure 25: Hematology deal upfront payment distribution, US$million - regulatory stage
  • Figure 26: Hematology deal upfront payment distribution, US$million - marketed stage
  • Figure 27: Summary median upfront payments by stage of development, 2009-2014
  • Figure 28: Hematology deals with milestone payments
  • Figure 29: Hematology deal milestone distribution, US$million - discovery stage
  • Figure 30: Hematology deal milestone distribution, US$million - preclinical stage
  • Figure 31: Hematology deal milestone distribution, US$million - phase I stage
  • Figure 32: Hematology deal milestone distribution, US$million - phase II stage
  • Figure 33: Hematology deal milestone distribution, US$million - phase III stage
  • Figure 34: Hematology deal milestone distribution, US$million - regulatory stage
  • Figure 35: Hematology deal milestone distribution, US$million - marketed stage
  • Figure 36: Hematology deals with royalty rates, %
  • Figure 37: Hematology deal royalty rate distribution, US$million - discovery stage
  • Figure 38: Hematology deal royalty rate distribution, US$million - preclinical stage
  • Figure 39: Hematology deal royalty rate distribution, US$million - phase I stage
  • Figure 40: Hematology deal royalty rate distribution, US$million - phase II stage
  • Figure 41: Hematology deal royalty rate distribution, US$million - phase III stage
  • Figure 42: Hematology deal royalty rate distribution, US$million - regulatory stage
  • Figure 44: Summary median royalty rate by stage of development, 2009-2014
  • Figure 45: Top hematology deals by value since 2009
  • Figure 46: Top hematology deals signed by bigpharma value since 2009
  • Figure 47: Online partnering resources
  • Figure 48: Forthcoming partnering events
Show More
Pricing
Get Notified
Email me when related reports are published